Table 3 Serum WFA+-M2BP performance in estimation of liver fibrosis stage in chronic hepatitis B/C patients.
Cut-off value | AUC | 95% CI | Sensitivity | Specificity | p value | |
|---|---|---|---|---|---|---|
Total; n = 412 | ||||||
F0-F1 vs F2-F4 | 1.03 | 0.670 | 0.622–0.715 | 67.23 | 61.82 | <0.0001 |
F0-F2 vs F3-F4 | 1.90 | 0.697 | 0.651–0.741 | 43.15 | 87.13 | <0.0001 |
F0-F3 vs F4 | 2.45 | 0.705 | 0.658–0.749 | 41.50 | 89.81 | <0.0001 |
HBV; n = 240 | ||||||
F0-F1 vs F2-F4 | 1.03 | 0.637 | 0.573–0.698 | 58.71 | 66.67 | 0.0053 |
F0-F2 vs F3-F4 | 1.32 | 0.634 | 0.569–0.695 | 47.01 | 75.47 | 0.0002 |
F0-F3 vs F4 | 1.03 | 0.666 | 0.603–0.725 | 71.26 | 54.90 | <0.0001 |
HCV; n = 172 | ||||||
F0-F1 vs F2-F4 | 2.21 | 0.698 | 0.624–0.766 | 44.87 | 93.75 | 0.0007 |
F0-F2 vs F3-F4 | 2.21 | 0.792 | 0.723–0.850 | 59.81 | 89.23 | <0.0001 |
F0-F3 vs F4 | 2.45 | 0.801 | 0.734–0.858 | 66.67 | 83.93 | <0.0001 |